ozarelix
Ozarelix is a peptide gonadotropin-releasing hormone antagonist which is or was under development by AEterna Zentaris Inc. and Spectrum Pharmaceuticals as a long-acting injection formulation for the treatment of prostate cancer. It has also been investigated for the treatment of endometriosis, but no development has been reported. The drug was previously under investigation for the treatment of benign prostatic hyperplasia and Alzheimer's disease as well, but development for these indications was discontinued. As of June 2015, it was in phase II clinical trials for prostate cancer. It seems to no longer be under development. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2007 (NCT00427219)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Gonadotropin-releasing hormone receptorANTAGONIST
GNRHR antagonist
- Progonadoliberin-1ANTAGONIST
GNRH1 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOzarelix ↗
- ChEMBLCHEMBL2108312 ↗
Also known as
- ac-d-nal(2)-d-phe(4cl)-d-pal(3)-ser-nme-tyr-d-hcit-nle-arg-pro-d-ala-nh2
- d-63153
- d-63153
- ozarelix
- ozarelix
- ozarelix
- ozarelix
- ozarelix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01252693 | Phase 2 | Nov 1, 2010 | Spectrum Pharmaceuticals |
| NCT00743184 | Phase 2 | Sep 1, 2008 | Spectrum Pharmaceuticals |
| NCT00427219 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2007 | Spectrum Pharmaceuticals |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spectrum Pharmaceuticals | For profit | 3 | 3 | 2 | 2007 |